$18.52 +0.64 (%) Sarepta Therapeutics Inc - NASDAQ

Jun. 24, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Sarepta Says FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C.

    Benzinga | Jan. 20, 2016 | 19:44PM EST
  2. Benzinga's Top Downgrades

    Benzinga | Jan. 19, 2016 | 09:30AM EST
  3. Sarepta drops on FDA release

    IBD | Jan. 15, 2016 | 18:43PM EST
  4. Sarepta Plummets As FDA Slams Muscular Dystrophy Drug

    IBD | Jan. 15, 2016 | 12:53PM EST
  5. BioMarin Muscular Dystrophy Drug Rejected By FDA

    IBD | Jan. 14, 2016 | 12:29PM EST
  6. FDA Panel Seen As Bad For BioMarin, Good For Sarepta

    IBD | Nov. 25, 2015 | 14:34PM EST
  7. BioMarin Drug's Future In Doubt After FDA Panel Vote

    IBD | Nov. 24, 2015 | 18:41PM EST
  8. KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers

    IBD | Nov. 21, 2015 | 08:15AM EST
  9. Benzinga's Top Initiations

    Benzinga | Oct. 23, 2015 | 08:20AM EST
  10. PTC Stock Seesaws On Muscular Dystrophy Drug Data

    IBD | Oct. 15, 2015 | 18:54PM EST
  11. Sarepta Therapeutics Inc. Not Giving Back Gains

    Benzinga | Oct. 1, 2015 | 11:26AM EST
  12. Sarepta Stock Soars On New Muscular-Dystrophy Data

    IBD | Oct. 1, 2015 | 11:19AM EST
  13. Benzinga's Volume Movers

    Benzinga | Oct. 1, 2015 | 10:36AM EST
  14. Jobs Data Weaken Stock Futures; Early Risers: Verisk, Sarepta

    IBD | Oct. 1, 2015 | 09:12AM EST
  15. Sarepta Therapeutics Announces Additional Long-Term Efficacy and Safety Data from Pivotal Phase IIb Program of Eteplirsen for Treatment of Duchenne Muscular Dystrophy

    Benzinga | Oct. 1, 2015 | 07:00AM EST
  16. Sarepta Offers Corporate Update, Recent Data from Phase IIb Study of Eteplirsen for DMD

    Benzinga | Sep. 25, 2015 | 08:32AM EST
  17. Sarepta Therapeutics Announces New England Journal of Medicine Publication of Phase I Clinical Data of Marburg Drug Candidate, AVI-7288, Supporting Safety of the PMOplusĀ® platform

    Benzinga | Jul. 22, 2015 | 17:06PM EST
  18. 2 DMD drugs make progress

    IBD | Jun. 29, 2015 | 18:45PM EST
  19. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD | Jun. 29, 2015 | 10:18AM EST
  20. Sarepta Therapeutics Completes NDA Submission to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

    Benzinga | Jun. 29, 2015 | 07:01AM EST
  21. Benzinga's Top Upgrades

    Benzinga | Jun. 22, 2015 | 09:07AM EST
  22. Benzinga's Top Downgrades

    Benzinga | May. 21, 2015 | 08:50AM EST
  23. Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings

    GuruFocus | May. 20, 2015 | 19:28PM EST
  24. Wednesday's Pre-Market Insights: Yahoo! Inc. ...

    GuruFocus | May. 20, 2015 | 18:24PM EST
  25. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD | May. 20, 2015 | 11:45AM EST
  26. Benzinga's Volume Movers

    Benzinga | May. 20, 2015 | 10:23AM EST
  27. Benzinga's Top Upgrades

    Benzinga | May. 20, 2015 | 09:16AM EST
  28. Stock Futures Aim For Mixed Open; Sarepta Soars, Etsy Heads South

    IBD | May. 20, 2015 | 09:06AM EST
  29. SunTrust Robinson Humphrey Upgrades Sarepta Therapeutics To Buy

    Benzinga | May. 20, 2015 | 08:58AM EST
  30. Benzinga's Top Upgrades

    Benzinga | May. 6, 2015 | 09:04AM EST
  31. Steven Cohen Keeps on Buying Biotechnological Companies

    GuruFocus | May. 4, 2015 | 18:48PM EST
  32. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD | Feb. 19, 2015 | 16:59PM EST
  33. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval

    Benzinga | Feb. 17, 2015 | 13:54PM EST
  34. Top 5 Biotech Stocks That The Smart Money Doesn't Like

    Benzinga | Feb. 17, 2015 | 12:17PM EST
  35. Who Ignited The Rally In Sarepta Therapeutics?

    Benzinga | Feb. 17, 2015 | 12:13PM EST
  36. 10 Biotech Stories You Might've Missed This Week

    Benzinga | Jan. 15, 2015 | 13:18PM EST
  37. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4

    Benzinga | Jan. 13, 2015 | 11:34AM EST
  38. Big Short Interest On These 5 Biotech Stocks

    Benzinga | Jan. 12, 2015 | 15:36PM EST
  39. Mid-Day Market Update: Foundation Medicine Shares Jump Following Deal With Roche; Crude Oil Slides Over 4%

    Benzinga | Jan. 12, 2015 | 12:55PM EST
  40. Mid-Morning Market Update: Markets Tumble; Shire To Acquire NPS Pharmaceuticals For $5.2 Billion

    Benzinga | Jan. 12, 2015 | 11:37AM EST
  41. Morning Market Losers

    Benzinga | Jan. 12, 2015 | 09:54AM EST
  42. Merger Monday Moving Stocks Monday Morning

    Benzinga | Jan. 12, 2015 | 09:48AM EST
  43. Benzinga's Top #PreMarket Losers

    Benzinga | Jan. 12, 2015 | 08:15AM EST
  44. Sarepta Therapeutics Falls Following 6-Minute Walk Test Results

    Benzinga | Jan. 12, 2015 | 08:13AM EST
  45. Viral Investing: Ebola Drug Makers' Varied Strategies

    IBD | Dec. 26, 2014 | 16:09PM EST
  46. Stocks Hitting 52-Week Lows

    Benzinga | Dec. 12, 2014 | 10:09AM EST
  47. Market Mixed Amid Plan To Spend $300 Million On Ebola Vaccines

    Benzinga | Dec. 11, 2014 | 14:14PM EST
  48. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD | Nov. 24, 2014 | 10:22AM EST
  49. Morning Market Movers

    Benzinga | Nov. 24, 2014 | 09:46AM EST
  50. Sarepta Therapeutics Shares Trending Higher Amid Sector M&A

    Benzinga | Nov. 24, 2014 | 09:20AM EST
Trading Center